๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital72 The First Affiliated Hospital of Zhengzhou University39 Merck Sharp & Dohme LLC27 AbbVie21 Novartis Pharmaceuticals20
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhengzhou

921 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
NCT06447779Herpes Zoster
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Shijiazhuang, Zhengzhou, Wuhan, Kunming
2024-07-13
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Active, closed
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
NCT06372925Plaque, Atherosclerotic
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
Not yet open
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
NCT06492317HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
20
Zhengzhou
2024-07-06
Active, closed
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
NCT06462469Steroid-refractory Acute Graft Versus Host Disease
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
ARTEMIS-008๏ผšHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3
460
Beijing, Harbin, Zhengzhou, Changchun, Shenyang, Jinan, Shanghai, Guangzhou
2024-07-04
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT06474455Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Not yet open
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
NCT06472479Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Not applicable
66
Hefei, Zhengzhou, Nanjing, Beijing
2024-07-01
Recruiting
DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis
NCT06527963Arteriovenous Fistula, Angioplasty, Balloon, Hemodialysis Access Failure
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-07-01
Not yet open
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
NCT06500091Soft Tissue Sarcoma, Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim
Phase 1/2
768
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations
NCT06479343Intracranial Arteriovenous Malformations
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
170
Guangzhou, Zhengzhou, Nanjing, Changchun, Shenyang, Jinan, Beijing, Chengdu
2024-06-27
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Anhui Sheng, Beijing, Guangzhou, Zunyi, Shijiazhuang, Zhengzhou, Changsha, Wuhan
2024-06-25
Recruiting
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
NCT06536400Solid Tumors
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
Phase 1
63
Beijing, Harbin, Zhengzhou, Jinan, Shanghai
2024-06-24
Active, closed
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06378177Head and Neck Squamous Cell Carcinoma
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
The Impact of Lifestyle Intervention on Weight and Fertility in Obese Males
NCT06339840Obesity, Weight Loss, Male Fertility, Artificial Insemination
Third Affiliated Hospital of Zhengzhou University
Not applicable
98
Zhengzhou
2024-06-20
Recruiting
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
NCT06368921Solid Tumor
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
30
Guangzhou, Zhengzhou, Jinan
2024-06-19
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
Application of HFNC for the Prevention of Hypoxemia During Perioperative Anesthetic-induced Intubation in Children: A Randomized Controlled Clinical Trial
NCT06425406High-flow Nasal Cannula, Children, Pre-oxygenation
Henan Provincial People's Hospital
Not applicable
48
Zhengzhou
2024-06-15
Recruiting
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
NCT06508983Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xiโ€™an
2024-06-14
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Phase 1
70
Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan
2024-06-14
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Mobile Applet for Weight Management in Obese Heart Failure Patients
NCT06455878Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction
Heart Health Research Center
Not applicable
830
Beijing, Guangzhou, Langfang, Jixi, Luoyang, Shangqiu, Xinyang, Zhengzhou
2024-06-06
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
NCT06450067B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
A Trail of Sperstentยฎ Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Recruiting
Effectiveness of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure
NCT06493292Hemodialysis Access Failure
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-06-01
Not yet open
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
NCT06465238NSCLC
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2024-06
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Amgen
Phase 1
120
Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun
2024-05-29
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Recruiting
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1/2
260
Beijing, Harbin, Tianjin, Wuhan, Zhengzhou
2024-05-23
Recruiting
IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes
NCT06118840Intracranial Aneurysm, CT Angiography, Deep Learning, Double Bind Interaction
Jinling Hospital, China
Not applicable
6,450
Hefei, Wuhu, Guiyang, Zhengzhou, Shiyan, Nanjing, Xuzhou, Changchun
2024-05-20
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Active, closed
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
NCT06396039Relapsing Multiple Sclerosis
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Recruiting
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
NCT06202625Thrombocytopenia, Stem Cell Transplant Complications
Peking University People's Hospital
Phase 2/3
142
Beijing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-05-13
Recruiting
Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAs
NCT07131020Stable COPD Patients
Henan University of Traditional Chinese Medicine
Not applicable
120
Zhengzhou
2024-05-11
Active, closed
A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma
NCT06742879Follicular Lymphoma
Zhengzhou University
Observational
37
Zhengzhou
2024-05-01
Not yet open
Screening for High-risk Chronic Obstructive Pulmonary Disease
NCT06350305High-risk COPD
Henan University of Traditional Chinese Medicine
Observational
3,600
Zhengzhou
2024-05-01
Not yet open
REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)
NCT06373692Bronchial Asthma
Henan University of Traditional Chinese Medicine
Observational
1,508
Zhengzhou
2024-05-01
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 2
155
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian
2024-04-29
Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473Pancreatic Cancer
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
NCT07011186Myeloid Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Recruiting
Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)
NCT06365502Acute Coronary Syndrome (ACS)
Harbin Medical University
Not applicable
1,860
Beijin, Zunyi, Daqing, Harbin, Jiamusi, Mudanjiang, Zhengzhou, Wuhan
2024-04-16
Recruiting
REspiratory diSEAse cohoRt Studies of CHinese Medicine for ILD (RESEARCH-ILD)
NCT06577753Interstitial Lung Disease
Henan University of Traditional Chinese Medicine
Observational
5,000
Zhengzhou
2024-04-15
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
Auditory Restoration and Outcomes After Gene Therapy and Cochlear Implantation: a PRospective Cohort Analysis (AURORA)
NCT06237790Hearing Loss, Genetic Disease, Speech Perception
Eye & ENT Hospital of Fudan University
Observational
180
Beijing, Zhengzhou, Changsha, Nanchang, Shanghai, Chengdu
2024-04-06
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
By invitation
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
NCT06370416Non-small Cell Lung Cancer
Henan Cancer Hospital
Phase 2
41
Zhengzhou
2024-04-02
Recruiting
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
NCT06241781Adult
Grit Biotechnology
Phase 2
83
Beijing, Fuzhou, Shenzhen, Guilin, Haโ€™erbin, Luoyang, Zhengzhou, Wuhan
2024-04-02
Recruiting
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
NCT06749730Unresectable Biliary Tract Carcinoma
Henan Cancer Hospital
Phase 2
63
Zhengzhou
2024-04-01
Not yet open
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
NCT06318884Non-Hodgkin Lymphoma, B-cell
Sinocelltech Ltd.
Phase 1
76
Beijing, Zhengzhou, Tianjin
2024-04
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Recruiting
Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)
NCT06284642Aneurysmal Subarachnoid Hemorrhage
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Recruiting
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
NCT07008703Cancer Pain
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1/2
132
Zhengzhou
2024-03-27
Active, closed
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426Allergic Rhinitis
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Recruiting
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT06222671Axial Spondyloarthritis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
180
Beijing, Chongqing, Zhengzhou, Nanjing, Shenzhen
2024-03-22
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Recruiting
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
NCT06752746Polycythemia Vera
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
Recruiting
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
NCT06375733Large B-cell Lymphoma
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
51
Nanning, Zhengzhou
2024-03-20
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
NCT06767813Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
NCT06294691Acute Graft-versus-host Disease
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Recruiting
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06313957Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1
42
Beijing, Zhengzhou
2024-03-14
Recruiting
Standardized Procedure for Intracranial Drug-Eluting Stenting in the Treatment of Intracranial Atherosclerotic Stenosis
NCT06857058Intracranial Atherosclerotic Stenosis
Sino Medical Sciences Technology Inc.
Not applicable
300
Zhengzhou
2024-03-08
Recruiting
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
NCT06306456Non-Small Cell Lung Cancer With EGFR Mutation
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2
94
Hefei, Zhengzhou, Changsha, Nanjing, Shanghai, Linhai
2024-03-05
Recruiting
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
NCT06546150KRAS G12D, T Cell Therapy
Henan Cancer Hospital
Phase 1
30
Zhengzhou
2024-03-01
Recruiting
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
NCT06747728Brain Glioma
The First Affiliated Hospital of Zhengzhou University
Not applicable
20
Zhengzhou
2024-03-01
Active, closed
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
NCT06294678Acute Graft-versus-host Disease
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
Recruiting
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
NCT06316960AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
Children's Hospital of Soochow University
Phase 2
50
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-03-01
Recruiting
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
NCT06329973Metastatic Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase 1/2
70
Zhengzhou
2024-02-28
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
1,400
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Recruiting
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
NCT06293014Colorectal Cancer
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2024-02-23
Recruiting
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
NCT06221748Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
NCT06241846Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
Henan Cancer Hospital
Phase 1/2
45
Zhengzhou
2024-02-22
Recruiting
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
NCT06225804Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Active, closed
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435Carcinoma, Non-Small-Cell Lung
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Hefei, Fuzhou, Foshan, Guangzhou, Jiangmen, Nanning, Luoyang, Zhengzhou
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Not yet open
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06236997Small Cell Lung Carcinoma
Henan Cancer Hospital
Phase 2
48
Zhengzhou, Wuhan
2024-02-10
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
Genmab
Phase 3
1,095
Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha
2024-02-05
Recruiting
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
NCT06188624Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Recruiting
Myasthenia Gravis Registry in China
NCT06241521Myasthenia Gravis
Huashan Hospital
Observational
1,500
Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang
2024-02-01
Recruiting
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557Advanced NSCLC, Advanced Endometrial Cancer
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Recruiting
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT05956587Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156Advanced Melanoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Recruiting
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069SCLC
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
NCT06186414Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
152
Beijing, Guangzhou, Haerbin, Zhengzhou, Wuhan, Changsha, Jinan, Qingdao
2024-01-23
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06345365Acute Myeloid Leukaemia
Zhongnan Hospital
Phase 3
154
Zhengzhou, Huanggang, Jingzhou, Shiyan, Wuhan, Xianning, Xiaogan, Yichang
2024-01-18
Recruiting
Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
NCT06478927Hepatocellular Carcinoma
Henan Cancer Hospital
Not applicable
22
Zhengzhou
2024-01-15
Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
Zhejiang University
Observational
3,600
Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou
2024-01-11
Recruiting
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
NCT06219356Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Recruiting
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
NCT06208410Advanced Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2
306
Zhengzhou
2024-01-11
Recruiting
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
NCT06278454Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer, Lymph Node Metastases
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
Recruiting
Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule
NCT06673121Pulmonary Nodule, Cohort Study, Traditional Chinese Medicine
Third Affiliated Hospital of Henan University of Traditional Chinese Medicine
Observational
5,000
Zhengzhou
2024-01-03
Recruiting
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
NCT06152107Severe Emphysema
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase โ…ก Clinical Trial
NCT06176534Advanced Breast Cancer, Treatment, HR Low/HER2 Negative
Henan Cancer Hospital
Phase 2
240
Zhengzhou
2024-01-01
Rows per page Showing 501–600 of 921
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 921 of those studies with a site in Zhengzhou.

How many clinical trials are recruiting in Zhengzhou?

553 of the 921 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 163 have not yet opened recruitment, 191 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.